Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sufenidone Phase II/III in Idiopathic Pulmonary Fibrosis
NCT06125327Phase 3Recruiting
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sufenidone in idiopathic pulmonary fibrosis (IPF), sponsored by Guangzhou JOYO Pharma. Started Jun 2023; status: recruiting.
02
Drugs
sufenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06125327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125327.